Posts by David Etchison
2022 Legislative Reception (photo gallery)
2022 Legislative Reception (photo gallery) NCBIO held its 2022 Legislative Reception on Wednesday, June 22, at the North Carolina Museum of History in Raleigh. The event was well attended by NCBIO members who were joined by a number of state senators, including Life Science Caucus Co-Chair Sen. Mike Woodard and Sens. Lisa Barnes, Sydney Batch,…
Read MoreSupply chain during pandemic discussed at June Biomanufacturers Forum meeting
Representatives of Merck and NCBIO discussed the supply-chain difficulties and issues the COVID-19 pandemic created for the bioscience industry at the quarterly NCBIO Biomanufacturers Forum meeting held Wednesday, June 1, at the NC Biotechnology Center.
Read MoreMedical Device Forum discusses current FDA regulatory environment
NCBIO members got an overview of the Food and Drug Administration’s regulatory environment for medical devices both during the pandemic and now at the NCBIO Medical Device Forum held May 11 at the NC Biotechnology Center.
Read MoreLead gifts from Alexandria Real Estate, Biogen, Hatteras push Taylor scholarship fund past $200,000
The Samuel M. Taylor Memorial Scholarship Fund created by NCBIO at the North Carolina Community Colleges Foundation Inc. has exceeded $200,000 in gifts and pledges with leadership gifts coming from Alexandria Real Estate Equities, Biogen and Hatteras Venture Partners.
Read MoreBIO: CMS decision enormous setback for Alzheimer’s patients, dangerous infringement on FDA autonomy
BIO: CMS decision enormous setback for Alzheimer’s patients, dangerous infringement on FDA autonomy On April 7, the Centers for Medicare and Medicaid Services held to its original decision to limit coverage of the Biogen’s Alzheimer’s disease treatment Aduhelm — along with other drugs like it — to clinical trials. Michelle McMurry-Heath, M.D., Ph.D., president and…
Read MoreNCBIO forum explores moving technology through funding phases
A high quality board of directors and valuable outside partnerships are two advantages that biotech startups would do well to cultivate, according to the expert panelists assembled for the NCBIO Emerging Company and Technology Forum held Wednesday, March 16, at the NC Biotechnology Center.
Read MoreNCBIO Roadmap to Diversity event offers guidance for member DEI initiatives
NCBIO members gathered at the NC Biotechnology Center Wednesday, March 9, to seek inspiration and guidance in pursuing their companies’ diversity, equity and inclusion goals. Some key takeaways from the discussions included the need to weave DEI into everything the company does; it can’t stand alone.
Read MoreBiotech joins efforts to aid in humanitarian relief in Ukraine
Biotech joins efforts to aid in humanitarian relief in Ukraine The biotech and life sciences industry is coming together to donate a range of critical medical supplies, equipment, and medications to the people of Ukraine. “The conflict in Ukraine and violence from Russia defies international law, norms and modern sensibilities,” said BIO President and CEO…
Read MoreCMS decision not to cover Alzheimer’s treatment a bad one
CMS decision not to cover Alzheimer’s treatment a bad one NCBIO stands in solidarity with patient advocates and industry leaders in opposing the Centers for Medicare and Medicaid Services’ draft proposal to restrict coverage for current and future Alzheimer’s drugs targeting beta amyloid, a known hallmark of the disease. Restricting coverage is a bad idea…
Read MoreBMF presenters share lessons learned commissioning facilities during pandemic
At the NCBIO Biomanufacturers Forum held online Feb. 23, representatives from FUJIFILM Diosynth Biotechnologies, Lilly and Project Farma shared what they had learned about commissioning new facilities and equipment during the during the COVID-19 pandemic.
Read More